Meeder Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Meeder Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,241	Closed	-$130K	–	2278
2020 Q3	$130K	Buy	+5,241	New	+$137K	0.01%	710
2020 Q2	–	Sell	-2,699	Closed	-$41K	–	2541
2020 Q1	$41K	Buy	2,699 +1,076	+66%	+$22.3K	﹤0.01%	992
2019 Q4	$26K	Buy	1,623 +580	+56%	+$8.99K	﹤0.01%	1272
2019 Q3	$14K	Buy	+1,043	New	+$12.8K	﹤0.01%	1428
2019 Q1	–	Sell	-614	Closed	-$12K	–	1900
2018 Q4	$12K	Buy	+614	New	+$13.5K	﹤0.01%	1201
2018 Q1	–	Sell	-127	Closed	-$5K	–	1781
2017 Q4	$5K	Buy	+127	New	+$3.65K	﹤0.01%	1329
2017 Q2	–	Sell	-505	Closed	-$11K	–	1919
2017 Q1	$11K	Sell	505 -254	-33%	-$5.22K	﹤0.01%	845
2016 Q4	$16K	Buy	+759	New	+$12.7K	﹤0.01%	687

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Meeder Asset Management's RVNC Position: Q4 2020 in Review

Meeder Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2020, closing a stake of 5,241 shares — an estimated $130K sold.

Meeder Asset Management first reported a position in RVNC in Q4 2016 and held it in 8 quarters. The position peaked at $130K in Q3 2020. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2020.

Meeder Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Meeder Asset Management sold 5,241 Revance Therapeutics, Inc. shares in Q4 2020, an estimated $130K.
Meeder Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2016 and held it in 8 quarters.
Meeder Asset Management's Revance Therapeutics, Inc. position peaked at $130K in Q3 2020.
151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2020.

Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.